{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:18:53Z","timestamp":1780503533439,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["TL1 TR000120-03"],"award-info":[{"award-number":["TL1 TR000120-03"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM104936"],"award-info":[{"award-number":["P20GM104936"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ijantimicag.2020.105898","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T19:53:55Z","timestamp":1578686035000},"page":"105898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Activity of pulmonary vancomycin exposures versus planktonic and biofilm isolates of methicillin-resistant Staphylococcus aureus from cystic fibrosis sputum"],"prefix":"10.1016","volume":"55","author":[{"given":"Nicholas S.","family":"Britt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Hazlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca T.","family":"Horvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael M.","family":"Liesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly E.","family":"Steed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.105898_bib0001","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0002","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.gene.2014.02.040","article-title":"CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease","volume":"540","author":"Bonadia","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0003","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1378\/chest.09-0132","article-title":"Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005","volume":"136","author":"Razvi","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0004","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ppul.21198","article-title":"Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008","volume":"45","author":"Emerson","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0005","series-title":"Annual data report","year":"2011"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0006","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200802-327OC","article-title":"Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis","volume":"178","author":"Dasenbrook","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0007","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0008","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1106\/4WVW-ACLD-EKV6-MBJJ","article-title":"Management of pulmonary disease in patients with cystic fibrosis","volume":"14","author":"Robinson","year":"2001","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0009","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1128\/AAC.00712-11","article-title":"Penetration of vancomycin into epithelial lining fluid in healthy volunteers","volume":"55","author":"Lodise","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/47.4.399","article-title":"A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital","volume":"47","author":"Wootton","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0011","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1139\/m97-144","article-title":"Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa","volume":"43","author":"Ghani","year":"1997","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0012","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1099\/jmm.0.45969-0","article-title":"Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung","volume":"54","author":"Sriramulu","year":"2005","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2180-12-181","article-title":"Characterization of biofilm-like structures formed by Pseudomonas aeruginosa in a synthetic mucus medium","volume":"12","author":"Haley","year":"2012","journal-title":"BMC Microbiol"},{"issue":"64","key":"10.1016\/j.ijantimicag.2020.105898_bib0014","first-page":"e3857","article-title":"Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung","author":"Kirchner","year":"2012","journal-title":"J Vis Exp"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0015","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0016","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model","volume":"48","author":"LaPlante","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0017","series-title":"Methods for determining bactericidal activity of antimicrobial agents; approved guideline","year":"1999"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0018","series-title":"26th Annual North American Cystic Fibrosis Conference; 11\u201313 October 2012","article-title":"AeroVanc\u2014phase I study of vancomycin inhalation powder","author":"Jouhikainen","year":"2012"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0019","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1128\/AAC.50.2.527-533.2006","article-title":"Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible S. aureus","volume":"50","author":"Sieradzki","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/dkw453","article-title":"Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia","volume":"72","author":"Britt","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0021","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1128\/AAC.02714-15","article-title":"Vancomycin 24-hour area under the curve\/minimum bactericidal concentration ratio as a novel predictor of mortality in methicillin-resistant Staphylococcus aureus bacteremia","volume":"60","author":"Britt","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0022","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1128\/JB.00059-15","article-title":"Coculture of Staphylococcus aureus with Pseudomonas aeruginosa drives S. aureus towards fermentative metabolism and reduced viability in a cystic fibrosis model","volume":"197","author":"Filkins","year":"2015","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00873-17","article-title":"Pseudomonas aeruginosa alters Staphylococcus aureus sensitivity to vancomycin in a biofilm model of cystic fibrosis infection","volume":"8","author":"Orazi","year":"2017","journal-title":"MBio"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0024","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1128\/AAC.00455-10","article-title":"Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm","volume":"54","author":"Parra-Ruiz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40121-014-0055-5","article-title":"Evaluation of high-dose daptomycin versus vancomycin alone or combined with clarithromycin or rifampin against Staphylococcus aureus and S. epidermidis in a novel in vitro PK\/PD model of bacterial biofilm","volume":"4","author":"Hall Snyder","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0026","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jac\/dkn513","article-title":"Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus","volume":"63","author":"Rose","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0027","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1128\/AAC.01642-08","article-title":"In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains","volume":"53","author":"LaPlante","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0028","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcf.2011.05.002","article-title":"Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?","volume":"10","author":"Stressmann","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0029","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1073\/pnas.1120577109","article-title":"Decade-long bacterial community dynamics in cystic fibrosis airways","volume":"109","author":"Zhao","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0030","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/jac\/dkq292","article-title":"Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"65","author":"Rose","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0031","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcf.2018.07.005","article-title":"Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis","volume":"18","author":"Dezube","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2020.105898_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009528.pub2","article-title":"Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis","volume":"11","author":"Waters","year":"2012","journal-title":"Cochrane Database Syst Rev"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:43:39Z","timestamp":1778766219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920300376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0924857920300376"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105898","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of pulmonary vancomycin exposures versus planktonic and biofilm isolates of methicillin-resistant Staphylococcus aureus from cystic fibrosis sputum","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105898"}}